Pieris: Public Equity Report: Palvella lands on NASDAQ via Pieris merger
JUL 26, 2024 | 11:25 AM PDT | BIOCENTURY | FINANCEPUBLIC EQUITY REPORT: PALVELLA LANDS ON NASDAQ VIA PIERIS MERGERBY Plus: Verastem's follow-on and Hangzhou Jiuyuan's IPO planshttps://www.biocentury.com/article/653070/public-equity-report-palvella-lands-on-nasdaq-via-pieris-merger© 2024 BioCentury Inc. All Rights Reserved
Read full article »
Pieris is a Massachusetts-based biotechnology company that develops and commercializes anticalin-derived drugs for the treatment of cancer and respiratory diseases.
Read more